Kizoo Technology Capital is a Karlsruhe-based venture capital firm focused on early-stage companies working on the biological drivers of aging and age-related disease. It invests primarily in rejuvenation biotech, life sciences, and drug discovery, often acting as a lead or high-conviction specialist investor. Its model is thesis-driven and strongly oriented around long-term scientific transformation rather than short-cycle venture trends.

The firm has built a strong position in longevity and regenerative medicine, including neuro-relevant investments such as Reservoir Neuroscience and Cellvie. Kizoo’s broader ecosystem, including its connection to Forever Healthy and the Undoing Aging community, gives it unusually deep thematic alignment around therapies targeting the root causes of aging. That makes it particularly relevant to companies working on neurodegeneration, vascular aging in the brain, or other age-associated neurological decline.

Kizoo invests internationally, with strongest activity across Europe and the United States. For neurotech and neuro-biotech founders, it is most relevant where the company sits within the longevity framework rather than purely device-led neurotechnology. It stands out as a specialist source of patient capital for companies addressing the biological basis of brain aging and related disorders.